Elsevier

The Lancet

Volume 335, Issue 8686, 17 February 1990, Page 418
The Lancet

LETTERS to the EDITOR
"Founder" effect in different families with haemophilia B mutation

https://doi.org/10.1016/0140-6736(90)90259-8Get rights and content

References (10)

  • Ar Thompson, Molecular biology of the hemophilias, Prog Hemostas Thrombos ((in...
  • Va Geddes et al.

    A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IX-Vancouver

    J Biol Chem

    (1989)
  • J. Ware et al.

    Genetic defect responsible for the dysfunctional protein: factor IX-Long Beach

    Blood

    (1988)
  • Sg Spitzer, Bj Warn-Cramer, Ck Kasper, Sp Bajaj, Replacement of 397 Ile by Thr in the clotting protease factor IXa (Los...
  • Pr Winship et al.

    Detection of polymorphisms at cytosine phosphoguanidine dinucleotides and diagnosis of haemophilia B carriers

    Lancet

    (1989)
There are more references available in the full text version of this article.

Cited by (39)

  • The past and future of haemophilia: diagnosis, treatments, and its complications

    2016, The Lancet
    Citation Excerpt :

    No causative gene variation was identified in a small proportion (<3%) of patients with haemophilia B.27–29 Unlike in haemophilia A, in haemophilia B no common frequent genetic variation, such as intron 22 inversion, has been identified. However, 20–30% of cases of mild haemophilia B are caused by roughly ten founder gene variants.30,31 Next-generation sequencing provides enhanced opportunities to characterise molecular defects in patients with haemophilia, particularly in those whose molecular defect has not been determined yet.32

  • Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors

    2004, Blood
    Citation Excerpt :

    As a result, better sustained circulating levels of FIX than FVIII after an infusion would tend to reduce the number of recurrent bleeding episodes. In addition, a substantial proportion of patients has been shown to have mutations of the hemophilia B gene (founders effects) that are associated with a mild phenotype despite a measured factor activity level in the moderate range.7 An examination of data collected on all UDC participants regardless of age or severity revealed that, overall, persons with hemophilia B consistently reported fewer bleeds and had less ROM limitation than those with hemophilia A. Further study of this issue is needed.

  • The Hemophilias

    1995, Advances in Genetics
  • Biology of inherited coagulopathies: Factor IX

    1992, Hematology/Oncology Clinics of North America
  • Neonatal Hemophilia A

    2022, Consultant
View all citing articles on Scopus
View full text